Actively Recruiting
ATATcH Alternating Treatment Plans for Advanced Cancer
Led by Rutgers, The State University of New Jersey · Updated on 2026-04-30
150
Participants Needed
11
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
CONDITIONS
Official Title
ATATcH Alternating Treatment Plans for Advanced Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients 18 years of age or older
- Histologically or cytologically confirmed advanced lung cancer (stage IV NSCLC) or recurrent/metastatic squamous cell carcinoma of the head and neck
- ECOG performance status of 0 to 2
- Measurable or non-measurable disease as assessed by imaging within 4 weeks prior to study registration
- No prior systemic chemotherapy or immunotherapy for advanced/metastatic disease (with some exceptions for prior non-metastatic treatment)
- Adequate organ and marrow function as defined by laboratory tests within 14 days prior to randomization
- Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception
- Ability to understand and willingness to sign informed consent
- Patients with treated brain metastases without evidence of progression are eligible
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible
- Patients with controlled hepatitis B or cured hepatitis C infection are eligible
You will not qualify if you...
- Presence of small cell carcinoma or mixed histologies with small cell component
- Known EGFR mutations (except exon 20 insertion), BRAF V600 mutations, MET exon 14 skipping, or ALK or ROS1 translocations treatable with oral tyrosine kinase inhibitors
- Pre-existing peripheral neuropathy grade 2 or higher (for lung squamous cell carcinoma arm)
- Active autoimmune disease requiring systemic treatment in the past 2 years
- Active infections including active tuberculosis or severe infection within 4 weeks prior to randomization
- History of solid organ or stem-cell transplantation
- Use of systemic immunosuppressive therapy within 7 days prior to randomization (with exceptions for low-dose steroids or local therapies)
- History of severe hypersensitivity to study drugs or similar antibodies
- Receipt of live vaccines within 30 days prior to randomization
- Pregnant or breastfeeding women
- Significant cardiovascular disease within 3 months prior to randomization
- Other serious illness or organ dysfunction that would compromise safety or study evaluation
- Use of other investigational agents during therapy
- Uncontrolled or symptomatic hypercalcemia
- Untreated brain metastases or leptomeningeal disease
- Patients unable or unwilling to comply with study procedures or contraception requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Trinitas Hospital and Comprehensive Cancer Center
Elizabeth, New Jersey, United States, 07207
Actively Recruiting
2
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, United States, 08690
Actively Recruiting
3
RWJBarnabas Health - Jersey City
Jersey City, New Jersey, United States, 07304
Actively Recruiting
4
RWJBarnabas Health - Monmouth Medical Center Southern Campus
Lakewood, New Jersey, United States, 08701
Actively Recruiting
5
RWJBarnabas Health - Saint Barnabas Medical Center
Livingston, New Jersey, United States, 10457
Actively Recruiting
6
RWJBarnabas Health - Monmouth Medical Center
Long Branch, New Jersey, United States, 07740
Actively Recruiting
7
RWJ Barnabas Health - Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States, 08901
Not Yet Recruiting
8
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903
Actively Recruiting
9
RWJBarnabas Health - Newark Beth Israel Medical Center
Newark, New Jersey, United States, 07112
Actively Recruiting
10
Robert Wood Johnson Somerset Hospital
Somerville, New Jersey, United States, 08876
Actively Recruiting
11
RWJBarnabas Health - Community Medical Center
Toms River, New Jersey, United States, 08755
Actively Recruiting
Research Team
M
Missak Haigentz, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here